Abstract
Background
The tumor microenvironment consists of stromal cells, extracellular matrix, and physicochemical properties (e.g., oxygenation, acidification). An important element of the tumor niche are cancer-associated fibroblasts (CAFs). They may constitute up to 80% of the tumor mass and share some features with myofibroblasts involved in the process of wound healing. CAFs can facilitate cancer progression. However, their interaction with melanoma cells is still poorly understood.
Methods
We obtained CAFs using conditioned media derived from primary and metastatic melanoma cells, and via co-culture with melanoma cells on Transwell inserts. Using 2D and 3D wound healing assays and Transwell invasion method we evaluated CAFs’ motile activities, while coverslips with FITC-labeled gelatin, gelatin zymography, and fluorescence-based activity assay were employed to determine the proteolytic activity of the examined cells. Western Blotting method was used for the identification of CAFs’ markers as well as estimation of the mediators of MMPs’ (matrix metalloproteinases) expression levels. Lastly, CAFs’ secretome was evaluated with cytokine and angiogenesis proteomic arrays, and lactate chemiluminescence-based assay.
Results
Acquired FAP-α/IL6-positive CAFs exhibited elevated motility expressed as increased migration and invasion ratio, as well as higher proteolytic activity (area of digestion, MMP2, MMP14). Furthermore, fibroblasts activated by melanoma cells showed upregulation of the MMPs’ expression mediators’ levels (pERK, p-p38, CD44, RUNX), enhanced secretion of lactate, several cytokines (IL8, IL6, CXCL1, CCL2, ICAM1), and proteins related to angiogenesis (GM-CSF, DPPIV, VEGFA, PIGF).
Conclusions
Observed changes in CAFs’ biology were mainly driven by highly aggressive melanoma cells (A375, WM9, Hs294T) compared to the less aggressive WM1341D cells and could promote melanoma invasion, as well as impact inflammation, angiogenesis, and acidification of the tumor niche. Interestingly, different approaches to CAFs acquisition seem to complement each other showing interactions between studied cells.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12964-022-00871-x.
Background
Melanoma is a skin cancer characterized by a high mortality rate [1]. Currently, several forms of targeted- and immunotherapies against melanoma are in clinical use, however, in the case of the majority of patients drug resistance develops rapidly. One of the factors that affect this phenomenon is the melanoma microenvironment, which consists of neighboring cells such as cancer-associated fibroblasts (CAFs), cancer-associated adipocytes, keratinocytes, and immune cells as well as physicochemical properties like acidification, oxygenation, and extracellular matrix (ECM) proteins [2, 3].
Fibroblasts are a major cellular component of the melanoma niche, which may constitute up to 80% of the tumor mass [4]. Normal fibroblasts can suppress melanoma development through the recruitment of immune cells in a paracrine way. Nevertheless, melanoma secretes different factors such as transforming growth factor-beta (TGFβ) and Nodal (a member of TGF superfamily), leading to activation of normal fibroblasts towards pro-tumorigenic CAFs, which are similar to myofibroblasts activated during the wound healing process [5–8]. Cancer-associated fibroblasts are characterized by increased expression of fibroblasts-activation protein-alpha (FAP-α), alpha-smooth muscle actin (α-SMA), and fibroblasts-specific protein 1 (FSP-1). However, activated fibroblasts are a heterogeneous group of cells and express these markers on different levels [9]. These cells may impact melanoma progression in various ways, e.g., by the production of matrix metalloproteinases, which facilitate melanoma invasion [10]. In addition, CAFs participate in the process of tumor angiogenesis through secretion of vascular endothelial growth factor and C-X-C-motif chemokine 12, which interacts with C-X-C-motif chemokine receptor 4 expressed on cancer cells and promotes endothelial cell recruitment [10, 11]. Activated fibroblasts also affect melanoma drug resistance development among others through the production of hepatocyte growth factor (HGF), basic fibroblasts growth factor (bFGF), and neuregulin 1, which support cell proliferation and tumor growth [10, 12, 13]. Moreover, the role of CAFs-secreted HGF in resistance acquisition is also described in the case of lung cancer [14].
In the area of the tumor microenvironment, cells may carry out anaerobic glycolysis, and as a result, an increased amount of lactate is produced, which is then transported to the extracellular space and contributes to raised external acidification [15]. The acidic niche leads to, important for cancer invasiveness, elevated adhesion [16], invasion [17], angiogenesis [18]. It corresponds also to the drug resistance [19, 20] and epithelial-mesenchymal transition (EMT) process through induction of extensive production of EMT-related proteins such as N-cadherin [21].
Recently, due to the essential role of CAFs in the formation of the tumor environment, this topic is widely studied, and some information concerning their function has been already discovered, but much—especially in the case of melanoma—remains unclear. Taking into account a great role played by CAFs in melanoma progression it is important to investigate interactions between these two cellular components of the tumor niche. Therefore, in our research we focused on the influence of melanoma cell lines derived from primary and metastatic tumors on normal human dermal fibroblasts (NHDF), considering their transformation into CAFs as well as cell properties associated with cancer progression.
Methods
Cell culture
Cancer-associated fibroblasts were differentiated from normal human dermal fibroblasts (Lonza) using four melanoma cell lines: A375 and Hs294T obtained from the American Type Culture Collection and WM1341D and WM9 cell lines purchased from Rockland Immunochemicals, Inc. Fibroblasts were cultured in FBM (Fibroblast Growth Basal Medium, Lonza) cell culture medium (supplemented with FGM™-2 SingleQuots™ from Lonza), whereas melanoma cells were grown in DMEM (Dulbecco’s Modified Eagle Medium) medium containing 4.5 g/l glucose and 1.5 g/l NaHCO3 supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, and antibiotics (10,000 U/ml penicillin, 10 mg/ml streptomycin, 25 µg/ml amphotericin B). Cells were cultured in 25 cm2 tissue culture flasks (VWR) at 37 °C in 5%CO2/95% humidified air and passaged twice a week using 0.25% trypsin/0.05% EDTA solution (IITD PAN, Wroclaw, Poland).
Acquisition of the melanoma-conditioned medium
To obtain melanoma-conditioned media, used further for fibroblasts’ activation, melanoma cells were cultured in 75 cm2 tissue culture flasks. After they reached 70–80% confluence, cells were washed three times with PBS, and then fresh medium without FBS was added. Cells were cultured for 72 h, then the medium was collected, centrifuged at 1000×g for 15 min, and frozen at − 20 °C. Media obtained from at least three distinct biological repetitions were refrozen, pooled, filtered through 0.22 µm filters (Googlab), aliquoted, and stored in − 20 °C. We obtained combined media regularly and fibroblasts in subsequent biological replications were treated each time with a conditioned medium from another pooling.
CAFs acquisition
CAFs were obtained from NHDF using transforming growth factor-beta (5 ng/ml, Corning) stimulation, or through culture in the presence of melanoma-conditioned media or indirect co-culture, with melanoma cells present on Transwell inserts (0.4 μm pores, Falcon) (Fig. 1). Fibroblasts were grown in differentiating conditions for seven days, with a single change of medium after four days of incubation. After this incubation time cells were collected and used for further experiments or—in the case of extracellular protein expression analysis—cells were washed three times with PBS and the culture media were changed to the fresh ones without FBS for another 72 h. Next, the media were harvested, centrifuged at 1000×g for 15 min, and frozen at − 20 °C.
Considering that in the experiments with melanoma-conditioned media, and in indirect co-culture, used media had to be suitable for two different types of cells, in both systems fibroblasts were grown in a combination of FBM and DMEM (1:1 ratio), therefore control for every experiment constitutes of fibroblasts cultured in such a medium. In the case of cells incubated with TGFβ, control cells were treated with TGFβ solvent (acetonitrile).
Western blot analysis
Cells were grown in the presence of melanoma-conditioned medium (CM) or in co-culture with melanoma cells, then transferred on ice, washed three times with PBS, and lysates were harvested by addition of urea buffer (50 mM Tris, pH 7.4, 5% SDS, 8.6% sucrose, 74 mM urea, 1 mM dichlorodiphenyltrichloroethane) supplemented with protease and phosphatase inhibitors cocktails (Sigma). Media used for estimation of secreted protein levels were obtained as described in the CAFs acquisition section and concentrated using Amicon® Ultra-4 Centrifugal Filters (Merck Millipore). Protein concentration was determined using standard BCA (Bicinchoninic acid) procedure (Thermofisher). Samples of the identical amount of protein (10 μg—cell lysates, 5 μg—conditioned media) were separated by 10% polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE) as reported by Laemmli [22] and then transferred to nitrocellulose membranes, as reported by Towbin et al. [23]. Antibodies directed against α-SMA (Sigma, A5228), FAP-α (Sigma, 2191M1), pERK (Cell Signaling, 9101), ERK (Cell Signaling, 9102), IL6 (Abcam, ab6672), RUNX2 (Santa Cruz, 390351), CD44 (GeneTex, GTX628895), p38 (Cell Signaling, 8690), p-p38 (Cell Signaling, 4511), caveolin 1 (Cell Signalling, 3267) as well as goat anti-rabbit and anti-mouse antibodies conjugated with horseradish peroxidase (Cell Signaling Technologies) were utilized according to the manufacturer’s protocols. Immunoblots were developed using the Clarity Western ECL Substrate (Bio-Rad), then scanned with ChemiDoc (Bio-Rad), and analyzed with ImageLab Software (ver. 6.0, Bio-Rad). At least three independent experiments were conducted. Results were normalized to Ponceau S staining.
2D and 3D wound healing
Cells were seeded into ImageLock 96-well plates (IncuCyte ImgeLock, Sartorius) coated with Matrigel (1 mg/ml) and incubated for 24 h. Then, standardized wounds were generated in all wells simultaneously using Wound Maker™ (Essen Bioscience). To evaluate invasion, the cell-free zone and the cells were covered with an additional Matrigel (1 mg/ml) layer. Then, FBM medium was added on the cell layer directly (migration assay) or on the top of 3D Matrigel matrices (invasion assay). Phase-contrast time-lapse images were captured with a time interval of 2 h, utilizing a 10 × objective in an IncuCyte® Live-Cell Analysis System. Cells were allowed to cover the wound for 36 h. Representative results were further analyzed using IncuCyte® Scratch Wound Cell Migration Software Module (Sartorius). The relative wound density represents the increase in the area covered by the cells over time. Three repetitions of the experiments, each condition consisting of three replicates, were performed.
Transwell invasion assay
Cell invasion tests were conducted using Transwell filters (8 µm pores, Falcon) placed in 24-well plates. Ahead of the experiment, CAFs obtained as previously described were starved for 24 h in serum-free FBM medium. Then, cells were seeded in medium without FBS onto each Transwell filter coated with Matrigel (1 mg/ml). In the bottom of the well medium containing 20% FBS served as a chemoattractant. After 24 h, non-invading cells and Matrigel present on the upper side of the filters were removed. Cells that invaded through the membrane were fixed with 4% formaldehyde; nuclei were stained with Hoechst 33342 and counted under the fluorescent microscope. The results of experiments are presented as a relative invasion factor (%). The number of control cells which invaded through the Transwell filters constitutes 100%. The experiments were performed three times, and each independent experiment was executed in triplicate.
Proliferation assay
The Cell Proliferation Kit II (XTT) (Roche) was used according to the manufacturer’s protocol. Briefly, CAFs were seeded in 96-well plates. The XTT labeling mixture was added in parallel samples at time 0 (T0) and after 24 h (T24) of cell growth. After 3 h of incubation in 37 °C absorbances at 450 nm were measured and obtained values were background corrected. Based on the absorbance, the mean proliferation rate was calculated by dividing T24 by T0. Control cells’ proliferation was set as 100%. The experiments were conducted on at least three biological repetitions in triplicate for each condition.
Fluorescent-gelatin degradation assay
The assays were performed according to the protocol described by Mazurkiewicz et al. [24]. Poly-L-lysine-coated coverslips (Corning) were washed with PBS and then fixed with 0.5% glutaraldehyde for 15 min. Next, the coverslips were placed on a 30 μl drop of gelatin labeled with fluorescein (FITC), incubated for 10 min, and rinsed with PBS. Then, sodium borohydride (5 mg/ml) was used for quenching the residual reactive groups. After washing with PBS, cells were seeded in 24-well plates containing a prepared before coverslips and incubated at 37 °C. After 8 h, cells were fixed with 4% formaldehyde, permeabilized with 0.1% Triton X-100, and stained with Alexa Fluor 568 phalloidin to visualize filamentous actin. Confocal images were captured using Leica SP8 confocal microscope and LAS X software (ver. 3.3.0, Leica). Places of degraded gelatin were visible as dark areas that lack fluorescence in the FITC channel in the bright green, fluorescent gelatin matrix.
Analysis was performed in Fiji software [25] employing scripts written in Fiji Macro language to automate the procedure. A single image subjected for analysis could contain a part of a single cell, a few parts of cells, a cell, a few cells, or a combination of the aforementioned situations. Image analysis was divided into two parts: in the first part the object of interest (i.e., at least a part of the cell) was segmented and its area was determined and assigned as “F-actin mask’s area” and the second part involved segmentation of the digested regions and their area determination. Gelatin-FITC proteolytic activity was defined as “digested area”/”F-actin mask’s area” × 100%. General workflow for the analysis of Gelatin-FITC digestion activity is presented in Additional file 3: Figure S3. Experiments were conducted in three repetitions.
MMP14 activity assay
To assess MMP14 activity the SensoLyte 520 MMP14 Assay Kit (AnaSpec) was used. CAFs were obtained as previously described, then they were washed with PBS and harvested in assay buffer containing 0.1% Triton-X 100 and incubated for 10 min on ice. Further, samples were centrifuged at 2500×g for 10 min at 4 °C, and supernatants were transferred into fresh tubes. Protein concentration was measured using a BCA assay. Samples with the same amount of protein (ca. 10 µg) were incubated with an activator for 2 h at 37 °C. Next, the substrate was added, and the enzymatic reaction was performed for 30 min at 37 °C, and then stopped with a stop solution. The fluorescence of the product was measured (Ex/Em = 475/500 nm) using the GloMax Discover plate reader (Promega). For each experiment, the MMP14 activity was calculated compared to the control cells. Control was set as 100% of activity. Experiments were conducted in three repetitions; each condition was performed in two replicates.
Gelatin zymography
The activity of secreted gelatinases was determined using cell-conditioned media. Following fibroblasts to CAFs transformation, cells were washed three times with PBS, and fresh medium without FBS was added, after 72 h of incubation in 37 °C, the medium was collected and concentrated using Amicon® Ultra-4 Centrifugal Filters (Merck Millipore). Next, protein concentration was determined using BCA (Thermofisher) assay, and cell-conditioned media were analyzed on SDS–polyacrylamide gels containing gelatin (1 mg/ml). The gels were stained with Coomassie Brilliant Blue R-250 (Sigma). Brighter stripes on gels were identified as the places of active gelatin degradation by MMPs. Gels were imaged with ChemiDoc (Bio-Rad) and densitometry of at least three biological replicates was performed using ImageJ software.
Cytokine and angiogenesis arrays
To establish the composition of CAFs secretome a Proteome Profiler Human Cytokine and Angiogenesis Array Kits (R&D Systems) were utilized. The tests allow for the detection of 36 or 55 different cytokines and chemokines or angiogenesis-related proteins, respectively, thanks to antibodies spotted on the nitrocellulose membrane. The experiment was conducted according to the manufacturer’s protocol. Briefly, conditioned media collected from control cells, fibroblasts treated with CM from WM1341D, and WM9 (each sample containing 25 µg of protein) were mixed with biotinylated detection antibodies. These mixes were then added onto nitrocellulose membranes containing primary antibodies dots and incubated overnight. Next, the membranes were washed, and the signal was detected using streptavidin-HRP. A chemiluminescent signal was measured using ChemiDoc Imaging System (BioRad) and analyzed with ImageLab software (Bio-Rad). The densitometric signal was background corrected and then normalized to a reference spot (mean) for each membrane.
Lactate secretion level
To evaluate the level of lactate secreted by CAFs, Lactate-Glo™ Assay (Promega) was used. In this test, lactate present in the medium undergoes oxidation catalyzed by lactate dehydrogenase, which is coupled with the reduction of NAD+. NADH, in turn, is used in pro-luciferin to luciferin reduction, utilized then to produce chemiluminescence. Analyzed media were collected as referred to in the CAFs acquisition section. Experiments were performed according to the manufacturer’s protocol. Luminescence was measured using the GloMax Discover plate reader (Promega). The luminescence value acquired from the control cells’ medium was set as 100%. Experiments were performed in three biological repetitions; each sample was conducted in triplicate.
Statistical analysis
All data are given as means ± standard deviation (SD), and their significance was evaluated with GraphPad Prism 7 software applying one-way ANOVA followed by Tukey’s test or Kruskal–Wallis (in the case of gelatin-FITC digestion analysis).
Results
In our experiments, we used four melanoma cell lines differing in invasiveness: derived from primary tumors—WM1341D and A375, as well as WM9 and Hs294T isolated from melanoma metastases. However, when we compared the influence of these cells on fibroblasts’ activity, we were taking into account not only their origin but also properties connected to cancer aggressiveness. Characterization of: WM1341D, A375, WM9, and Hs294T described earlier by Makowiecka et al. [26] revealed higher proteolytic activity, invadopodia formation ability, and a higher rate of migration and invasion in the case of A375, WM9, Hs294T cells in comparison to WM1341D cells. Therefore, in the further part of this manuscript, the WM1341D cell line is defined as the one with a less aggressive phenotype, and A375, WM9, Hs294T lines as highly aggressive cell lines.
CAFs identification
First, three methods of fibroblasts differentiation were optimized, starting with the treatment of fibroblasts with TGFβ, which is known to activate this cell type [5]. However, there is a variety of melanoma-derived molecules, which may transform normal fibroblasts into CAFs, e.g., Nodal [6]. Therefore, we decided to use two other methods: fibroblasts (NHDF) cultured with melanoma-conditioned media (CM) or with melanoma cells present on the Transwell inserts (INS) (Fig. 1), and obtained CAFsCM and CAFsINS, respectively. To compare the effects exerted by primary and metastatic melanoma on normal fibroblasts, we performed experiments using four different melanoma cell lines—differing in the origin.
We have assessed activation of fibroblasts based on the presence of markers typical for CAFs (α-SMA, FAP-α) using Western Blot analysis. Fibroblasts activated by TGFβ were characterized by a high α-SMA level (Additional file 1: Fig. S1), whereas fibroblasts cultured with melanoma CM and from indirect co-culture displayed a high FAP-α level (Fig. 2A). Cells treated with TGFβ did not exhibit changes in activation of proteins connected to cancer progression and involved in the mitogen-activated protein kinase (MAPK) pathway, which abnormal regulation may lead to increased or uncontrolled cell proliferation and resistance to apoptosis of cancer cells. Research into the MAPK pathway has shown it to be important for some cancers, expressed as an increase in phosphorylation of extracellular signal-regulated kinase (ERK) (Additional file 1: Fig. S1). This effect was observed in the case of CAFs co-cultured with melanoma and melanoma CM-treated CAFs (Additional file 1: Fig. S1). Since CAFs co-cultured with melanoma (INS) and cultured in the presence of melanoma conditioned media (CM) seem to better reflect in vivo conditions, thus further experiments were performed using only the model of CAFsCM and CAFsINS.
We also confirmed the transformation of fibroblasts towards CAFs through the observation of elevated extracellular interleukin 6 (IL6) level (Fig. 2B), which is characteristic of this type of cells. Moreover, fibroblasts cultured in the presence of metastatic melanoma secretome exhibited a higher level of FAP-α (in both experimental models—CAFsINS, CAFsCM), and IL6 (only in the case of CAFsCM) in comparison to cells incubated with melanoma cells derived from primary tumors (Fig. 2).
CAFs migration and invasion
In the next step, CAFs were characterized concerning the processes involved in metastasis formation. Migration-imitating cell movement in two-dimensional (2D) conditions, e.g., on the basement membrane surface was estimated using directional migration scratch assay. We observed a higher migration rate in the case of CAFsINS in comparison to normal fibroblasts (Fig. 3A), whereas we did not notice any difference between examined CAFsCM and control conditions. To evaluate the invasive ability of fibroblasts, we performed a 3D wound healing assay, in which cells were placed between two layers of Matrigel imitating basement membrane and, thus, in vivo conditions. The relative wound density was higher in CAFsINS co-cultured with metastasis-derived cell lines (WM9, Hs294T) in comparison to control cells and fibroblasts cultured in the presence of primary melanoma cell lines (WM1341D and A375) (Fig. 3B). We did not observe any significant differences in the case of CAFsCM invasion.
Further, invasion assays through Transwell inserts were conducted, where cells invaded through the Matrigel towards a chemoattractant added to the medium. A significant increase in the invasion capacity was observed in the case of CAFsCM and CAFsINS in comparison to control fibroblasts (Fig. 3C). To confirm that the observed changes in CAFs migration and invasion abilities are not the result of their enhanced cell division rate, proliferation assays were performed indicating no differences between CAFs and control cells (Additional file 2: Fig. S2).
Proteolytic activity of CAFs
Proteolytic enzymes secreted by cells during invasion digest ECM proteins and, in this way, form a pathway used by cancer cells to move through the tissue. Due to the fact, that we observed differences in invasion rate between normal fibroblasts and CAFs, we also compared their proteolytic activity. To realize this purpose a gelatin-FITC degradation assay was conducted, in which cells digested fluorescently-labeled gelatin leading to the appearance of black spots on a fluorescent green background. In addition, we stained filamentous actin (F-actin) using phalloidin conjugated to Alexa Fluor 568 to visualize actin cytoskeleton organization, including the occurrence of podosomes—cellular protrusions involved in cell movement. We detected changes in proteolysis patterns between normal fibroblasts and CAFs (Fig. 4A). Moreover, it was observed that CAFs digested gelatin-FITC to a higher extent than control fibroblasts (Fig. 4B).
The changes observed in gelatin-FITC degradation in CAFs compared to normal fibroblasts prompted us to further analyze the composition of proteases secreted by examined cells. We conducted gelatin zymography using conditioned cell culture media from fibroblasts and CAFs, in which digestion of the gelatin by proteases is visible as a transparent band on a dark background. We detected a higher MMP2 activity in CAFs media than in media collected from fibroblasts culture. Moreover, we have noted that metastatic melanoma led to a higher activity of MMP2 in CAFs than fibroblasts cultured in the presence of melanoma derived from primary tumors (Fig. 5A). Next, we performed an MMP14 activity assay and observed its higher activity in the case of fibroblasts derived from a culture with metastatic melanoma media in comparison to control cells (Fig. 5B). In the case of CAFsINS, we also observed such a tendency, but the results were not statistically significant.
To further unravel the basis of the increased MMPs’ activity, we analyzed proteins related to cell motility and signaling such as the MAPK pathway [27]. Western Blot analysis of CAFs’ lysates revealed a higher phosphorylation rate of ERK and p38 (Fig. 6A, B) in CAFs, compared to normal fibroblasts.
CD44 (Cluster of Differentiation 44) is a transmembrane hyaluronic acid receptor that can act as the organizing platform for MMPs and can be cleaved by proteases resulting in extra- and intracellular forms, where the latter one was reported to bind to runt-related transcription factor 2 (RUNX2) and work as a co-transcriptional factor for metastatic-related genes, e.g., MMP9 in prostate cancer [28, 29]. Therefore, we decided to estimate the level of CD44 in conditioned media and RUNX2 in lysates obtained from CAFs. We conducted Western Blot analysis and demonstrated a higher level of RUNX2 and CD44 in CAFs compared to fibroblasts (Fig. 6C, D), although these differences are statistically significant only in the case of CAFsCM.
Characterization of CAFs’ secretome
In our research, we focused on features of CAFs connected to cancer progression, which includes not only proteolysis but also angiogenesis and inflammation processes. Taking into account, that cells present in the tumor niche communicate with each other through direct interactions and in a paracrine manner [30], we selected representative melanoma cell lines derived from primary (WM1341D) and metastatic (WM9) tumors for fibroblasts activation, and performed profiling of human cytokine and angiogenesis factors in CAFs’ media. In Fig. 7 secreted proteins whose expression differs between control and CAFs are shown. In the case of cytokines, the secretion of at least five of them (i.e., CCL2 (i.e., C-C Motif Chemokine Ligand 2), CXCL1 (C-X-C Motif Chemokine Ligand 1), IL6, IL8, ICAM1 (Intercellular Adhesion Molecule 1)) is specifically induced in CAFs obtained using metastatic melanoma cells (WM9) and undetected in primary melanoma-derived CAFs (Fig. 7A, C). On the other hand, the treatment with WM9-conditioned medium seems to reduce angiogenic mediators secretion by CAFs with an exception of IL8, Granulocyte–macrophage colony-stimulating factor (GM-CSF), placental growth factor (PIGF), dipeptidyl‐peptidases IV (DPPIV), while it is maintained or even elevated (e.g., vascular endothelial growth factor A (VEGFA), Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) and Pentraxin 3 (PTX3)) in the case of WM1341D-derived CAFs.
An important factor, which modifies the cancer microenvironment and has an influence on cancer progression is also extracellular acidification induced by lactate secretion. Therefore, we estimated the level of lactate secreted by fibroblasts, under the influence of melanoma cells. Analysis of lactate level in CAFs’ media revealed extensive secretion of this metabolite after activation of fibroblasts by melanoma cells. Furthermore, in the case of CAFsINS, we observed higher lactate levels in CAFs co-cultured with more aggressive melanoma (A375, WM9, Hs294T) cells than those, which were grown in the presence of less aggressive WM1341D cells (Fig. 8A). Furthermore, metabolic reprogramming of CAFs, which results in increased lactate secretion can be triggered by downregulation of caveolin 1 (Cav-1) expression [31, 32]. We performed Western blot analysis and established that the level of caveolin-1 was reduced in CAFs compared to control cells (Fig. 8B).
Discussion
Fibroblasts are the major component of the tumor niche, especially in the case of skin cancer. At the tumor onset, they may suppress cancer development by induction of inflammation processes [34]. However, cancer cells are able to transform adjacent fibroblasts into cancer-associated ones, which are more supportive for their survival [13]. CAFs secrete several factors involved in cancer progression such as MMPs, cytokines, and growth factors [2, 10, 35]. Taking into account the great role played by CAFs in the modulation of the tumor microenvironment and cancer progression, it is important to investigate the molecular basis of the interactions between these two types of cells. Therefore, in this research, we focused on the influence exerted by melanoma cells on fibroblasts’ functions.
We established two different methods of CAFs acquisition based on commonly utilized systems: using melanoma-conditioned medium [36] and with melanoma cells present on Transwell inserts [37, 38]. Both approaches worked well, leading to fibroblasts’ activation identified by high FAP-α and IL6 levels, which are markers of this type of cells described in the literature [34, 39, 40]. In the first model, fibroblasts were treated with melanoma-conditioned media. This method might be characterized by a greater reproducibility of the obtained results between biological replications of experiments because only fibroblasts are a variable factor here (they may slightly change their phenotype from passage to passage). Despite the conditioned media are each time combined from several biological repetitions, their composition is not so fluctuating. In the case of the indirect co-culture, the reproducibility of the results may be lower, because both the fibroblasts and the melanoma cells can undergo some phenotypic changes with subsequent passages. Due to that, we observed lower standard deviation and, thus, statistically significant differences in the level of MMP2, MMP14, RUNX2, or CD44 in CAFs obtained by incubation with conditioned media, but not by co-culturing with melanoma cells present on Transwell inserts. However, a major advantage of the CAFsINS culture method is that cells grow in one environment and influence each other, modulating their responses, what may reflect conditions more similar to those prevailing in vivo. This may be the reason why we observed higher migratory and invasive abilities in CAFs obtained by indirect co-culture with melanoma cells, than those treated with melanoma CM. Due to the aforementioned distinctions, we decided that it was more appropriate to use both of these models in our research.
To investigate the differences in the effects exerted by primary tumor- and metastasis-derived melanoma cells on normal fibroblasts activity, we utilized four different melanoma cell lines: WM1341D, A375 (primary tumor-derived), and WM9, Hs294T (metastasis-derived). However, these cell lines differ not only due to their origin but also in aggressiveness. Therefore, during the analysis of our results, we focused on both aspects. We established that metastasis-derived melanoma stimulates motility and proteolytic activity of CAFs to a greater extent than primary tumor-derived melanoma cell lines. However, a higher level of activation and lactate secretion was triggered in CAFs by highly aggressive A375, WM9, Hs294T cell lines (where A375 is derived from the primary tumor) than by less aggressive WM1341D cells (also derived from the primary tumor). In this way, we have demonstrated that not only the origin but also aggressiveness of melanoma cells is important for CAFs activation.
Next, we analyzed the impact of melanoma on fibroblasts in terms of cancer progression. We detected changes in fibroblasts’ migration, invasion, and proteolytic activity—features significant for metastasis formation. Increased proteolysis of ECM in the tumor microenvironment may facilitate cancer cells’ invasion, as in this way, they form a pathway that can be used by other cells to move through the surrounding tissue [41–43]. A majority of studies concerning crosstalk between CAFs and melanoma have focused only on changes in melanoma motility under the influence of CAFs [38, 44–46]. Because cancer cells may move collectively together with fibroblasts [47–50], it is also important to investigate the migratory abilities of CAFs. Our results, indicating increased migration of CAFs compared to normal fibroblasts, are consistent with the study of the motility of CAFs treated with melanoma-derived exosomes [51, 52] and fibroblasts isolated from gastric cancer [53]. Furthermore, we demonstrated activation of the MAPK pathway (upregulated phosphorylation of ERK and p38) in CAFs, which may lead to increased proliferation and migration of these cells and, thus, enhance melanoma progression [54]. We also observed an enhanced level of RUNX2 and CD44—proteins connected to MMPs’ expression. In prostate cancer, an intracellular form of CD44—released upon extracellular domain cleavage—is transported into the nucleus, where it can bind to RUNX2 leading to its activation and subsequent increased MMPs expression [29]. It has not been yet reported in the case of melanoma-associated fibroblasts. We detected upregulation of all above-mentioned proteins from this pathway (CD44, RUNX2, MMPs) in CAFs, nevertheless, a conclusion that in CAFs this pathway is also present would require further experiments.
As secretome is an important part of the crosstalk between cells, we decided to analyze secretion patterns of CAFs by focusing on the molecules involved in the regulation of inflammation and angiogenesis using Cytokine and Angiogenesis Arrays. We detected higher levels of various cytokines, i.e., CCL2, IL8, CXCL1, GM-CSF, ICAM1, IL6; factors influencing angiogenesis, namely DPPIV and VEGF, and reduced secretion of angiogenin in CAFs compared to control cells. The increase in CCL2, IL8, and CXCL1 was already observed in melanoma-associated fibroblasts. Moreover, it was shown that highly invasive melanoma cells affect the expression of these proteins to a greater extent than less invasive melanoma [55]. Secretion of GM-CSF, DPPIV, ICAM1 and PIGF by melanoma-associated fibroblasts was not reported before.
It should be mentioned that GM-CSF is involved in immune cell activation, and it was tested as a form of monotherapy against melanoma. However, the drug based on GM-CSF was rejected at the stage of clinical trials due to low treatment efficiency [56]. On the other hand, in a melanoma mouse model, a positive correlation between GM-CSF expression and tumor growth has been observed [57]. As we detected this protein in CAFs’ medium, it is possible, that CAF-derived GM-CSF could influence melanoma progression.
Another protein, detected in CAFs secretome was ICAM1, which is present on the surface of many hematopoietic and nonhematopoietic cells and may act as an adhesive ligand for the integrins, indicating its involvement in cell-substrate adhesion [58]. Interestingly, pERK is described to activate the expression of ICAM1 in rat fibroblasts [59]. Moreover, it was shown that in melanoma patients, the presence of ICAM1 correlates with a worse prognosis [60]. In turn, PIGF is a member of the VEGF family. According to our best knowledge, secretion of PIGF by melanoma-associated fibroblasts has not been reported before. However, Aoki et al. demonstrated, that CAFs stimulate invasion of intrahepatic cholangiocarcinoma by PIGF secretion [61]. On the other hand, we observed a lower level of angiogenin in CAFs compared to control cells, which was shown by Song et al. to be crucial for bFGF-induced melanoma cell proliferation [62].
We also detected higher lactate levels in CAFs compared to control cells. Secreted lactate may cause tumor niche acidification, which in turn activates invasion and angiogenesis in cancer cells and thus corresponds to cancer progression [21]. Increased lactate secretion may stem from reduced caveolin 1 level in CAFs. Interestingly, data obtained by Wu et al. showed that loss of stromal Cav-1 expression was also linked to poor survival and increased metastatic potential in melanoma [33]. It seems that melanoma cells induce fibroblasts to enhance extracellular acidification that in turn might support tumor progression.
Taking into account that CAFs have a great impact on cancer progression, additional CAFs-directed therapy for melanoma suffering patients would be worth considering [40, 63]. It is especially important in the case of patients with metastases, as our research shows that fibroblasts are activated to a greater extent by metastatic melanomas cells compared to the ones derived from the primary tumor.
Conclusions
Concluding, the use of two different models imitating the relationship between melanoma-associated fibroblasts and melanoma cells within the microenvironment seems to be appropriate to gain a broader view of these cells’ crosstalk. Furthermore, the influence of melanoma cells on fibroblasts differs depending on cancer cells’ origin and their aggressiveness. In selected experiments, primary tumor-derived melanoma cells affected CAFs to a lesser extent compared to metastatic. Moreover, in some cases less aggressive WM1341D cells led to weaker responses of fibroblasts than highly aggressive melanoma cell lines (A375, WM9, Hs294T). We observed higher proteolytic activity and level of proteins connected to MMPs’ expression, as well as elevated migration and invasion ability of CAFs in comparison to normal fibroblasts, and these features may stimulate cancer progression (Fig. 9), therefore a combination therapy against melanoma and melanoma-associated fibroblasts might be promising.
Supplementary Information
Abbreviations
- BCA
Bicinchoninic acid
- bFGF
Basic fibroblasts growth factor
- CAFs
Cancer-associated fibroblasts
- CCL2
C-C motif chemokine ligand 2
- CD44
Cluster of differentiation 44
- CM
Conditioned medium
- CTRL
Control
- CXCL1
C-X-C motif chemokine ligand 1
- DMEM
Dulbecco’s Modified Eagle Medium
- DPPIV
Dipeptidyl peptidase IV
- ECM
Extracellular matrix
- EMT
Epithelial-mesenchymal transition
- ERK
Extracellular signal-regulated kinase
- FAP-α
Fibroblasts-activation protein alpha
- FBM
Fibroblast Growth Basal Medium
- FBS
Fetal bovine serum
- FSP-1
Fibroblasts-specific protein 1
- GM-CSF
Granulocyte–macrophage colony-stimulating factor
- HGF
Hepatocyte growth factor
- ICAM1
Intercellular adhesion molecule 1
- IGFB-2
Insulin-like growth factor binding protein 2
- IL6
Interleukin 6
- INS
Transwell inserts
- MAPK
Mitogen-activated protein kinase
- MIF
Macrophage migration inhibitory factor
- MMPs
Metalloproteinases
- NHDF
Normal human dermal fibroblasts
- PDGF A
Platelet-derived growth factor A
- PIGF
Placental growth factor
- PTX3
Pentraxin 3
- RUNX2
Runt-related transcription factor 2
- SDS
Sodium dodecyl sulfate
- TIMP-4
Tissue inhibitor of metalloproteinases 4
- TGFβ
Transforming growth factor-beta
- TSP-1
Thrombospondin 1
- uPA
Urokinase-type plasminogen activator
- VEGFA
Vascular endothelial growth factor A
- α-SMA
Alpha-smooth muscle actin
Author contributions
JM, AS, ED, KPG, MK, and MM performed the experiments and analyzed the data, JM and DN wrote the manuscript, AS, ED, KPG, MK, MM, MZ, RM participated in the review and edition of the manuscript. DN and RM were responsible for the supervision and funding acquisition. All authors read and approved the final manuscript.
Funding
This research was funded by the National Science Centre, Poland, with a grant received by Dorota Nowak (OPUS 15, No. 2018/29/B/NZ5/00967). Publication of this article was financially supported by the Excellence Initiative-Research University (IDUB) program for the University of Wroclaw.
Availability of data and materials
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
Declarations
Competing interests
The authors declare that there is no conflict of interest.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Justyna Mazurkiewicz and Aleksandra Simiczyjew equal contribution authorship.
References
- 1.Williams PF, Olsen CM, Hayward NK, Whiteman DC. Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer. 2011;129:1730–1740. doi: 10.1002/ijc.25804. [DOI] [PubMed] [Google Scholar]
- 2.Ruiter D, Bogenrieder T, Elder D, Herlyn M. Melanoma–stroma interactions: structural and functional aspects. Lancet Oncol. 2002;3:35–43. doi: 10.1016/S1470-2045(01)00620-9. [DOI] [PubMed] [Google Scholar]
- 3.Falcone I, Conciatori F, Bazzichetto C, Ferretti G, Cognetti F, Ciuffreda L, Milella M. Tumor microenvironment: implications in melanoma resistance to targeted therapy and immunotherapy. Cancers. 2020;12:2870. doi: 10.3390/CANCERS12102870. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2016;30:1002–1019. doi: 10.1101/gad.279737.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Busse A, Keilholz U. Role of TGF-β in Melanoma. Curr Pharm Biotechnol. 2011;12:2165–2175. doi: 10.2174/138920111798808437. [DOI] [PubMed] [Google Scholar]
- 6.Li Z, Zhang J, Zhou J, Lu L, Wang H, Zhang G, Wan G, Cai S, Du J. Nodal facilitates differentiation of fibroblasts to cancer-associated fibroblasts that support tumor growth in melanoma and colorectal cancer. Cells. 2019;8:538. doi: 10.3390/cells8060538. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Münster-Kühnel AK, Tiralongo J, Krapp S, Weinhold B, Ritz-Sedlacek V, Jacob U, Gerardy-Schahn R. Structure and function of vertebrate CMP-sialic acid synthetases. Glycobiology. 2004;14:43–51. doi: 10.1093/glycob/cwh113. [DOI] [PubMed] [Google Scholar]
- 8.Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle. 2006;5:1597–1601. doi: 10.4161/cc.5.15.3112. [DOI] [PubMed] [Google Scholar]
- 9.Räsänen K, Virtanen I, Salmenperä P, Grenman R, Vaheri A. Differences in the nemosis response of normal and cancer-associated fibroblasts from patients with oral squamous cell carcinoma. PLoS ONE. 2009 doi: 10.1371/JOURNAL.PONE.0006879. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Zhou L, Yang K, Andl T, Wickett RR, Zhang Y. Perspective of targeting cancer-associated fibroblasts in melanoma. J Cancer. 2015;6:1. doi: 10.7150/jca.10865. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Mazurkiewicz J, Simiczyjew A, Dratkiewicz E, Ziętek M, Matkowski R, Nowak D. Stromal cells present in the melanoma niche affect tumor invasiveness and its resistance to therapy. Int J Mol Sci. 2021;22:1–21. doi: 10.3390/ijms22020529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Capparelli C, Rosenbaum S, Berger AC, Aplin AE. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma. J Biol Chem. 2015;290:24267–24277. doi: 10.1074/jbc.M115.657270. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Busse A, Keilholz U. Role of TGF- in melanoma. Curr Pharm Biotechnol. 2011;12:2165–2175. doi: 10.2174/138920111798808437. [DOI] [PubMed] [Google Scholar]
- 14.Hu H, Piotrowska Z, Hare PJ, Chen H, Mulvey HE, Mayfield A, Noeen S, Kattermann K, Greenberg M, Williams A, et al. Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell. 2021;39:1531–1547.e10. doi: 10.1016/J.CCELL.2021.09.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–899. doi: 10.1038/nrc1478. [DOI] [PubMed] [Google Scholar]
- 16.Paradise RK, Lauffenburger DA, van Vliet KJ. Acidic extracellular pH promotes activation of integrin αvβ3. PLoS ONE. 2011 doi: 10.1371/journal.pone.0015746. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, Bailey K, Balagurunathan Y, Rothberg JM, Sloane BF, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013;73:1524–1535. doi: 10.1158/0008-5472.CAN-12-2796. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Sonveaux P, Copetti T, de Saedeleer CJ, Végran F, Verrax J, Kennedy KM, Moon EJ, Dhup S, Danhier P, Frérart F, et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS ONE. 2012 doi: 10.1371/journal.pone.0033418. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics: I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol. 2003;66:1207–1218. doi: 10.1016/S0006-2952(03)00467-2. [DOI] [PubMed] [Google Scholar]
- 20.Dratkiewicz E, Simiczyjew A, Mazurkiewicz J, Ziętek M, Matkowski R, Nowak D. Hypoxia and extracellular acidification as drivers of melanoma progression and drug resistance. Cells. 2021;10:862. doi: 10.3390/cells10040862. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Peppicelli S, Bianchini F, Torre E, Calorini L. Contribution of acidic melanoma cells undergoing epithelial-to-mesenchymal transition to aggressiveness of non-acidic melanoma cells. Clin Exp Metastasis. 2014;31:423–433. doi: 10.1007/s10585-014-9637-6. [DOI] [PubMed] [Google Scholar]
- 22.Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
- 23.Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 1979;76:4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Mazurkiewicz E, Mrówczyńska E, Simiczyjew A, Nowak D, Mazur AJ. A fluorescent gelatin degradation assay to study melanoma breakdown of extracellular matrix. Methods Mol Biol. 2021;2265:47–63. doi: 10.1007/978-1-0716-1205-7_3. [DOI] [PubMed] [Google Scholar]
- 25.Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676–682. doi: 10.1038/NMETH.2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Makowiecka A, Simiczyjew A, Nowak D, Mazur AJ. Varying effects of EGF, HGF and TGFγ on formation of invadopodia and invasiveness of melanoma cell lines of different origin. Eur J Histochem. 2016;60:230–238. doi: 10.4081/ejh.2016.2728. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Jiang L, Meng W, Yu G, Yin C, Wang Z, Liao L, Meng F. MicroRNA-144 targets APP to regulate AML1/ETO+ leukemia cell migration via the p-ERK/c-Myc/MMP-2 pathway. Oncol Lett. 2019;18:2034. doi: 10.3892/OL.2019.10477. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Anderegg U, Eichenberg T, Parthaune T, Haiduk C, Saalbach A, Milkova L, Ludwig A, Grosche J, Averbeck M, Gebhardt C, et al. ADAM10 is the constitutive functional Sheddase of CD44 in human melanoma cells. J Invest Dermatol. 2009;129:1471–1482. doi: 10.1038/jid.2008.323. [DOI] [PubMed] [Google Scholar]
- 29.Senbanjo LT, Aljohani H, Majumdar S, Chellaiah MA. Characterization of CD44 intracellular domain interaction with RUNX2 in PC3 human prostate cancer cells. Cell Commun. Signal. 2019;17:1. doi: 10.1186/s12964-019-0395-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Villanueva J, Herlyn M. Melanoma and the tumor microenvironment. Hoboken: Wiley; 2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Nwosu ZC, Ebert MP, Dooley S, Meyer C. Caveolin-1 in the regulation of cell metabolism: a cancer perspective. Mol Cancer. 2016;15:1–12. doi: 10.1186/s12943-016-0558-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Ha TK, Her NG, Lee MG, Ryu BK, Lee JH, Han J, Jeong SI, Kang MJ, Kim NH, Kim HJ, et al. Caveolin-1 increases aerobic glycolysis in colorectal cancers by stimulating HMGA1-mediated GLUT3 transcription. Cancer Res. 2012;72:4097–4109. doi: 10.1158/0008-5472.CAN-12-0448. [DOI] [PubMed] [Google Scholar]
- 33.Wu KN, Queenan M, Brody JR, Potoczek M, Sotgia F, Lisanti MP, Witkiewicz AK. Loss of stromal Caveolin-1 expression in malignant melanoma metastases predicts poor survival. Cell Cycle. 2011;10:4250–4255. doi: 10.4161/cc.10.24.18551. [DOI] [PubMed] [Google Scholar]
- 34.Lu C, Vickers MF, Kerbel RS. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci. 1992;89:9215–9219. doi: 10.1073/pnas.89.19.9215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Mazurkiewicz J, Simiczyjew A, Dratkiewicz E, Ziętek M, Matkowski R, Nowak D. Stromal cells present in the melanoma niche affect tumor invasiveness and its resistance to therapy. Int J Mol Sci. 2021;22:529. doi: 10.3390/ijms22020529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Pessotti DS, Andrade-Silva D, Serrano SMT, Zelanis A. Heterotypic signaling between dermal fibroblasts and melanoma cells induces phenotypic plasticity and proteome rearrangement in malignant cells. Biochim Biophys Acta Proteins Proteomics. 2020;1868:140525. doi: 10.1016/J.BBAPAP.2020.140525. [DOI] [PubMed] [Google Scholar]
- 37.Preisner F, Leimer U, Sandmann S, Zoernig I, Germann G, Koellensperger E. Impact of human adipose tissue-derived stem cells on malignant melanoma cells in an in vitro co-culture model. Stem cell Rev Rep. 2018;14:125–140. doi: 10.1007/S12015-017-9772-Y. [DOI] [PubMed] [Google Scholar]
- 38.Papaccio F, Kovacs D, Bellei B, Caputo S, Migliano E, Cota C, Picardo M. Profiling cancer-associated fibroblasts in melanoma. Int J Mol Sci. 2021 doi: 10.3390/IJMS22147255. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Dienus K, Bayat A, Gilmore BF, Seifert O. Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option. Arch Dermatol Res. 2010;302:725–731. doi: 10.1007/S00403-010-1084-X. [DOI] [PubMed] [Google Scholar]
- 40.Bellei B, Migliano E, Picardo M. A framework of major tumor-promoting signal transduction pathways implicated in melanoma-fibroblast dialogue. Cancers (Basel) 2020;12:1–22. doi: 10.3390/CANCERS12113400. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Tao L, Huang G, Song H, Chen Y, Chen L. Cancer associated fibroblasts: an essential role in the tumor microenvironment (review) Oncol Lett. 2017;14:2611–2620. doi: 10.3892/OL.2017.6497/HTML. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Shay G, Lynch CC, Fingleton B. Moving targets: emerging roles for MMPs in cancer progression and metastasis. Matrix Biol. 2015;44–46:200–206. doi: 10.1016/J.MATBIO.2015.01.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans. 2017;45:229. doi: 10.1042/BST20160387. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Ntayi C, Hornebeck W, Bernard P. Influence of cultured dermal fibroblasts on human melanoma cell proliferation, matrix metalloproteinase-2 ( MMP-2) expression and invasion in vitro. Arch Dermatol Res. 2003;1:236–241. doi: 10.1007/s00403-003-0429-0. [DOI] [PubMed] [Google Scholar]
- 45.Jobe NP, Rösel D, Dvořánková B, Kodet O, Lacina L, Mateu R, Smetana K, Brábek J. Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness. Histochem Cell Biol. 2016;146:205–217. doi: 10.1007/S00418-016-1433-8. [DOI] [PubMed] [Google Scholar]
- 46.Izar B, Joyce CE, Goff S, Cho NL, Shah PM, Sharma G, Li J, Ibrahim N, Gold J, Hodi FS, et al. Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferation. Pigment Cell Melanoma Res. 2016;29:656–668. doi: 10.1111/PCMR.12513. [DOI] [PubMed] [Google Scholar]
- 47.Saitoh M. Involvement of partial EMT in cancer progression. J Biochem. 2018;164:257–264. doi: 10.1093/JB/MVY047. [DOI] [PubMed] [Google Scholar]
- 48.Ilina O, Friedl P. Mechanisms of collective cell migration at a glance. J Cell Sci. 2009;122:3203–3208. doi: 10.1242/JCS.036525. [DOI] [PubMed] [Google Scholar]
- 49.Waldeland JO, Polacheck WJ, Evje S. Collective tumor cell migration in the presence of fibroblasts. J Biomech. 2020;100:109568. doi: 10.1016/J.JBIOMECH.2019.109568. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Hegerfeldt Y, Tusch M, Bröcker E-B, Friedl P. Collective cell movement in primary melanoma explants. Cancer Res. 2002;62:2125–2130. [PubMed] [Google Scholar]
- 51.Wang C, Wang Y, Chang X, Ba X, Hu N, Liu Q, Fang L, Wang Z. Melanoma-derived exosomes endow fibroblasts with an invasive potential via miR-21 target signaling pathway. Cancer Manag Res. 2020;12:12965–12974. doi: 10.2147/CMAR.S273718. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Strnadová K, Pfeiferová L, Přikryl P, Dvořánková B, Vlčák E, Frýdlová J, Vokurka M, Novotný J, Šáchová J, Hradilová M, et al. Exosomes produced by melanoma cells significantly influence the biological properties of normal and cancer-associated fibroblasts. Histochem Cell Biol. 2021 doi: 10.1007/S00418-021-02052-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Ishimoto T, Miyake K, Nandi T, Yashiro M, Onishi N, Huang KK, Lin SJ, Kalpana R, Tay ST, Suzuki Y, et al. Activation of transforming growth factor beta 1 signaling in gastric cancer-associated fibroblasts increases their motility, via expression of rhomboid 5 homolog 2, and ability to induce invasiveness of gastric cancer cells. Gastroenterology. 2017;153:191–204.e16. doi: 10.1053/J.GASTRO.2017.03.046. [DOI] [PubMed] [Google Scholar]
- 54.Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279–3290. doi: 10.1038/sj.onc.1210421. [DOI] [PubMed] [Google Scholar]
- 55.Li L, Dragulev B, Zigrino P, Mauch C, Fox JW. The invasive potential of human melanoma cell lines correlates with their ability to alter fibroblast gene expression in vitro and the stromal microenvironment in vivo. Int J Cancer. 2009;125:1796–1804. doi: 10.1002/ijc.24463. [DOI] [PubMed] [Google Scholar]
- 56.Dillman RO. An update on GM-CSF and its potential role in melanoma management. Melanoma Manag. 2020;7:MMT49. doi: 10.2217/MMT-2020-0011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Aliper AM, Frieden-Korovkina VP, Buzdin A, Roumiantsev SA, Zhavoronkov A. A role for G-CSF and GM-CSF in nonmyeloid cancers. Cancer Med. 2014;3:737–746. doi: 10.1002/CAM4.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Piela-Smith TH, Broketa G, Hand A, Korn JH. Regulation of ICAM-1 expression and function in human dermal fibroblasts by IL-4. J Immunol. 1992;148:1375–1381. [PubMed] [Google Scholar]
- 59.Sapna S, Shivakumar K. Substance P enhances soluble ICAM-1 release from adult rat cardiac fibroblasts by a p42/44 MAPK- and PKC-mediated mechanism. Cell Biol Int. 2007;31:856–859. doi: 10.1016/J.CELLBI.2007.01.031. [DOI] [PubMed] [Google Scholar]
- 60.Harning R, Mainolfi E, Bystryn J-C, Henn M, Merluzzi VJ, Rothlein R. Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res. 1991;51:5003–5005. [PubMed] [Google Scholar]
- 61.Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, Nikmaneshi MR, Kitahara S, Hato T, Chen X, et al. Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. Gut. 2021 doi: 10.1136/GUTJNL-2020-322493. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Song J, Wang J, Yang J, Jiang C, Shen W, Wang L. Influence of angiogenin on the growth of A375 human melanoma cells and the expression of basic fibroblast growth factor. Melanoma Res. 2006;16:119–126. doi: 10.1097/01.CMR.0000215029.62199.4C. [DOI] [PubMed] [Google Scholar]
- 63.Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q, Deng S, Zhou H. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;2021(6):1–35. doi: 10.1038/s41392-021-00641-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.